ERAS as of Oct 31 · 18:54 ET
ERASNasdaqPharmaceutical Preparations

Erasca, Inc. · Brief

Next report

11 days

Nov 11 · after closeest.Q3 FY26

Expected move

No implied move.

Implied vs realized

8 reportsHistory
0 of 8≥ implied
avg implied
±32.2%
avg realized
±3.4%
Mar 20 '25±85.0%▲+3.38%×0.04
May 13 '25±16.4%▼−4.51%×0.27
Aug 12 '25±85.0%▲+3.85%×0.05
Q3 FY25±18.7%▼−4.15%×0.22
Jan 20 '26±19.7%▲+2.45%×0.12
Q1 FY26±11.1%▼−7.03%×0.63
May 11 '26±8.4%▼−0.57%×0.07
Q2 FY26±13.2%▲+1.47%×0.11
quarterimplied−85%0+85%realized×
Q2 FY26±13.2%▲+1.47%×0.11
May '26±8.4%▼−0.57%×0.07
Q1 FY26±11.1%▼−7.03%×0.63
Jan '26±19.7%▲+2.45%×0.12
Q3 FY25±18.7%▼−4.15%×0.22
Aug '25±85.0%▲+3.85%×0.05
2 older reports
May '25±16.4%▼−4.51%×0.27
Mar '25±85.0%▲+3.38%×0.04
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 11 report · est.

Bull2 of 3

5disclosed supplier and customer ties in SEC filingsSEC filings
257managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2

8 of 8recent reports where the move came in under the options implied rangeEarnings history
6 of 23of the largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26
AI captions · Sep 28 '26once per report · top 2 per case

Linked exposure

ERAS report session

No linked exposure.

Latest changes

30 daysAll changes
Oct 28impliedImplied move: ±19.5% into Nov 11 earnings (Oct 28 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.